Michael Atkins

Michael Atkins is a leading melanoma oncologist who has contributed to establishing adjuvant immunotherapy standards for resected high-risk stage III melanoma. His research has examined prognostic biomarkers predicting adjuvant therapy outcomes and mechanisms of resistance in patients with BRAF-mutated and BRAF-wild-type melanoma. He has led or co-led multiple pivotal adjuvant and metastatic melanoma trials evaluating pembrolizumab, nivolumab, and combination checkpoint blockade. His translational work bridges clinical outcomes with tumor immune microenvironment characteristics to optimize patient selection for adjuvant strategies.